High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone

Blood. 2008 Jan 15;111(2):968-9. doi: 10.1182/blood-2007-10-119321.
No abstract available

Publication types

  • Comparative Study
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Boronic Acids / administration & dosage*
  • Bortezomib
  • Clinical Trials, Phase III as Topic
  • Dexamethasone / administration & dosage*
  • Female
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Male
  • Models, Biological*
  • Multiple Myeloma* / drug therapy
  • Multiple Myeloma* / metabolism
  • Multiple Myeloma* / mortality
  • Neoplasm Proteins / biosynthesis*
  • Predictive Value of Tests
  • Pyrazines / administration & dosage*
  • Risk Factors
  • Time Factors

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Neoplasm Proteins
  • Pyrazines
  • Bortezomib
  • Dexamethasone